Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Working Groups

Our overarching research goal is to create new and innovative strategies for improved and novel treatments, disease modification and eventually cures for neurodegenerative diseases. We are striving to understand the mechanisms of neurodegenerative diseases, and to create a dynamic structure for the advancement of research, innovation and education in the field. Ultimately, our research will improve functioning, health and quality of life of people living and ageing with these diseases.

In order to reach this goal, we aim to:

  1. Determine molecular and cellular mechanisms of pathogenesis in neurodegenerative disease
  2. Perform pioneering transplantation trials using stem cells
  3. Perform clinical trials using gene-transfer based therapy
  4. Develop new pharmacological approaches for disease-modifying and symptomatic therapies
  5. Perform leading translational research on cognitive dysfunction and other non-motor symptoms
  6. Develop and implement accurate biomarker and imaging tools for diagnostic purposes and outcome measures
  7. Develop, test and evaluate new health promoting interventions

For the redefined aims, translational working groups have been formed, with the following mission:
Benchmark progress, define milestones and deliverables for each aim - in terms of competitive science.


The translational working groups are the following:

1. Mechanisms of disease (adressing aim 1)

Convening members:
Gunnar Gouras
Jia-Yi Li


2. Cell therapy (adressing aim 2)

Convening members:  
Malin Parmar  
Anders Björklund


3. Gene therapy (addressing aim 3)

Convening members:  
Cecilia Lundberg
Tomas Björklund 


4. Translational pharmacology (addressing aim 4)

Convening members:  
Laurent Roybon
Roger Olsson


5. Cognitive dysfunction and non-motor symptoms (addressing aim 5)

Convening members:
Niklas Mattsson-Carlgren
Sebastian Palmqvist


6. Biomarkers and bioimaging (addressing aim 6)

Convening members:  
Markus Nilsson
Oskar Hanson


7. Outcome measures (addressing aim 7)

Convening members:
Jan Lexell
Maria H Nilsson